From: The roles of exosomal immune checkpoint proteins in tumors
Cancer | Expression of PD-L1 carried by TEXs | Effect | Material | Sample | References |
---|---|---|---|---|---|
HNSCC | ↑ | Disease progression | PB | 40 HNSCC patients | [52] |
PDAC | + | Shorter postoperative survival time | PB | 55 PDAC patients | [58] |
Melanoma | ↓ | Respond to treatment | PB | 18 melanoma patients | [63] |
NSCLC | ↓ | Respond to treatment | PB | 8 NSCLC patients | [63] |
Metastatic melanoma | ↑ | Distinguish melanoma patients from healthy donors | PB | Patients with stage III to IV melanoma and healthy donors | [57] |
Melanoma | ↑ | Fail to respond to the anti-PD-1 treatment | PB | Melanoma patients | [57] |
Melanoma | ↑ | T cell re-invigoration | PB | Melanoma patients on pembrolizumab therapy within 6 weeks | [57] |
Glioblastoma | ↑ | Larger glioblastoma tumor volume | PB | 21 glioblastoma patients | [56] |